CTOR

Pre-mercato: .83 -0.03 -3.49%

Citius Oncology Inc (CTOR)

Panoramica Notizia Cronologia dei prezzi Forum Previsione

Precedente Chiudi:

Volume 24 ore:

Relative Volume:

Capitalizzazione di mercato:

Utile/perdita netta:

Rapporto P/E:

Flusso di cassa netto:

1 W Prestazione:

1M Prestazione:

6M Prestazione:

1 anno Prestazione:

Intervallo 1D:

Intervallo di 1 settimana:

Portata 52W:

Citius Oncology Inc Stock (CTOR) Company Profile

Citius Oncology Inc

Healthcare (1165)

(908) 967-6677

11 COMMERCE DRIVE, CRANFORD

Prossima data di guadagno

Ultimi documenti SEC

CTOR's Discussions on Twitter

Confronta CTOR con altri titoli

Azioni	Prezzo	Cap. di mercato	Reddito	Reddito netto	Flusso di cassa	EPS
CTOR Citius Oncology Inc	0.86	61.54M	0	0	0	0.00
ZTS Zoetis Inc	161.91	72.50B	9.26B	2.49B	2.30B	5.47
TAK Takeda Pharmaceutical Co Adr	14.90	47.08B	30.25B	1.37B	5.08B	0.4257
HLN Haleon Plc Adr	10.18	45.99B	14.35B	1.85B	0	0.4023
TEVA Teva Pharmaceutical Industries Ltd Adr	15.29	17.52B	16.54B	-1.64B	749.00M	-1.45
ITCI Intra Cellular Therapies Inc	131.87	14.05B	612.78M	-86.37M	-62.91M	-0.87

Citius Oncology Inc Stock (CTOR) Upgrades & Downgrades

Data	Azione	Analista	Modifica della valutazione
2024-11-27	Iniziato	Maxim Group	Buy

Citius Oncology Inc Borsa (CTOR) Ultime notizie

Citius Oncology Inc Azioni (CTOR) Dati Finanziari

Non sono disponibili dati finanziari per Citius Oncology Inc (CTOR). Controlla altri titoli per ulteriori informazioni.

Citius Oncology Inc (CTOR)

Citius Oncology Inc Stock (CTOR) Company Profile

Confronta CTOR con altri titoli

Citius Oncology Inc Stock (CTOR) Upgrades & Downgrades

Citius Oncology Inc Borsa (CTOR) Ultime notizie

Citius Pharma secures $2 million in stock offering By Investing.com - Investing.com Australia

Citius Pharmaceuticals Announces $2 Million Registered Direct Offering of Common Stock - PR Newswire

Citius Secures Strategic $2M Funding to Accelerate LYMPHIR LaunchKey Details Revealed - Stock Titan

Citius Oncology (NASDAQ:CTOR) Shares Up 39.8% – Still a Buy? - Defense World

12 Health Care Stocks Moving In Tuesday's Pre-Market Session - Benzinga

3 Penny Stocks to Watch Now, 4/1/25 - TipRanks

Citius Oncology, Inc. (NASDAQ:CTOR) Is Expected To Breakeven In The Near Future - simplywall.st

Citius Oncology, Inc. Reports Fiscal First Quarter 2025 Financia - GuruFocus.com

Citius Pharma's LYMPHIR gains permanent J-code for billing - MSN

Citius Oncology (NASDAQ:CTOR) Issues Earnings Results - MarketBeat

Citius Pharmaceuticals, Inc. Reports Fiscal First Quarter 2025 Financial Results and Provides Business Update - The Malaysian Reserve

Citius Oncology, Inc. Reports Fiscal First Quarter 2025 Financial Results and Provides Business Update - 69News WFMZ-TV

Citius Oncology Inc. (CTOR) reports earnings - Quartz

CITIUS ONCOLOGY, INC. SEC 10-Q Report - TradingView

Citius Oncology Preps LYMPHIR Cancer Drug Launch While Strategic Review Unfolds - StockTitan

Citius Pharmaceuticals Secures Critical J-Code for LYMPHIR as Cash Reserves Hit $1.1M - Stock Titan

Citius Pharmaceuticals (NASDAQ:CTXR) Announces Issuance of Permanent J-Code for LYMPHIR by CMSOn February 6, 2025, Citius Pharmaceuticals, Inc. (NASDAQ:CTXR) disclosed in an 8-K filing that the company and its oncology subsidiary, Citius Oncol - Defense World

Citius Pharma’s LYMPHIR gains permanent J-code for billing By Investing.com - Investing.com Nigeria

Citius Pharma's LYMPHIR gains permanent J-code for billing By Investing.com - Investing.com Australia

Medicare Breakthrough: Citius's Cancer Drug LYMPHIR Gets Crucial Insurance CodeMajor Win for CTCL Patients - StockTitan

Citius Oncology (NASDAQ:CTOR) Shares Down 2%Here's What Happened - MarketBeat

Amendment: SEC Form 10-K/A filed by Citius Pharmaceuticals Inc. - Quantisnow

Citius Oncology, Inc. Reports Fiscal Full Year 2024 Financial Results and Provides Business Update - 69News WFMZ-TV

Citius Pharmaceuticals (NASDAQ: CTXR) Announces Progress in LYMPHIR Commercial Launch Preparation - Defense World

Citius Pharmaceuticals Announces $3 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules - BioSpace

Citius Pharmaceuticals Secures $3M Through Strategic Share Offering with 5-Year Warrants - StockTitan

Citius Pharmaceuticals and Citius Oncology Highlight LYMPHIR Commercial Launch Planned for the First Half of 2025 - PR Newswire

Citius Oncology to explore strategic alternatives - Yahoo Finance

Citius Oncology Engages Jefferies as Exclusive Financial Advisor to Explore Strategic Alternatives - The Malaysian Reserve

Citius Oncology Explores Strategic Options with Jefferies Following LYMPHIR FDA Approval - Stock Titan

Citius Pharma Reports 2024 Financial Results and Business Update - MSN

Citius Pharmaceuticals upgraded to Buy from Hold at D. Boral Capital - Yahoo Finance

Citius Pharmaceuticals (NASDAQ: CTXR) Reports Fiscal Full Year 2024 Financial Results and Provides Business Update - Defense World

Citius Oncology, Inc. Reports Earnings Results for the Full Year Ended September 30, 2024 - Marketscreener.com

Citius Pharmaceuticals, Inc. Reports Fiscal Full Year 2024 Financial Results and Provides Business Update - The Malaysian Reserve

Citius Pharmaceuticals Inc. (CTXR) reports earnings - Quartz

Citius Pharmaceuticals stock hits 52-week low at $2.52 - Investing.com

Major Improvements In Citius Oncology Inc (CTOR) Stock Need To Be Considered - Stocks Register

Citius Pharmaceuticals, Inc. and Citius Oncology, Inc. Announce LYMPHIR™ (Denileukin Diftitox-cxdl) Added to National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology - The Eastern Progress Online

“Market Movers: CTOR, CTNT, PNPN.V, KITT, SHIM – More Stocks Inside To Watch” - Barchart

Why Credo Technology Group Shares Are Trading Higher By 40%; Here Are 20 Stocks Moving Premarket - Benzinga

Maxim Group Begins Coverage on Citius Oncology (NASDAQ:CTOR) - Defense World

Loss-Making Citius Oncology, Inc. (NASDAQ:CTOR) Expected To Breakeven In The Medium-Term - Simply Wall St

Citius Oncology, Inc.'s (NASDAQ:CTOR) Path To Profitability - Yahoo Finance

Citius Pharmaceuticals to Host Investor Call to Discuss Topline Results of Phase 3 Trial of Mino-Lok Antibiotic Lock Solution - Marketscreener.com

Citius Pharmaceuticals Engages Financial Advisor for Oncology Subsidiary Spinoff - Marketscreener.com

Citius Pharma Advances Mino-Lok After Successful FDA Meeting, Phase 3 Trial Results | CTXR Stock News - StockTitan

CTOR stock touches 52-week low at $0.9 amid market challenges - Investing.com Canada

Citius Oncology Inc Azioni (CTOR) Dati Finanziari

Reddito

Reddito netto

Flusso di cassa

EPS

Simile a CTOR